Tafenoquine Truth: “Warriors Betrayed”…



ublished on Aug 28, 2016

Allied Veterans from the US, CAN, UK, AUS, IRE and probably others, over a generation have been administered Lariam – Mefloquine and in some cases – Tafenoquine.

Although many do not have lasting adverse effects from these anti malarial drugs, a sizeable minority appear likely to have received a lasting or permanent acquired brain injury (ABI)

The drugs were given to prevent malaria. Military users had little or no choice in being administered the drugs.

This ABI is a physical injury (not a “mental health” disorder) which results in a syndrome of chronic neurological and psychiatric symptoms, many of which the manufacturer acknowledges are “common” side effects in the case of Mefloquine.

Governments and militaries world wide are not doing enough for those affected…. Why?

This short vid highlights what may veterans and their families feel.

Warriors Betrayed …..

It is dedicated to the many men and women who took these drugs in good faith, to those who need our help and in particular to the many who have lost their battle worldwide.

And to their wonderful families.

Lest We Forget …

Want to know more?

To obtain more information go to The International Veterans Alliance http://www.imvallaince.org



EU health chief: children suffered ‘terrifying experiences’ from swine flu vaccine side effects


EU health chief: children suffered ‘terrifying experiences’ from swine flu vaccine side effects

European Health Commissioner Vytenis Andriukaitis said he wanted to prevent any more children suffering narcolepsy as a result of taking the swine flu vaccine Pandemrix.European Health Commissioner Vytenis Andriukaitis said he wanted to prevent any more children suffering narcolepsy as a result of taking the swine flu vaccine Pandemrix. (AFP PHOTO/Emmmanuel Dunand (Photo credit should read EMMANUEL DUNAND/AFP/Getty Images)

The EU Commissioner for Health and Food Safety has told i how Europe is preparing for another swine flu pandemic he hopes will avoid the previous “terrible outcome” where narcolepsy was triggered in around 100 British children following their vaccination against the disease.

Vytenis Andriukaitis, a heart surgeon, said the European Union, in conjunction with the World Health Organisation (WHO) and other agencies, is drawing up new plans following “lessons learned” on how the 2009/10 swine flu outbreak was handled.

A main goal is to “increase flexibility” by addressing the response needed for pandemics of differing severity, from unknown to mild, moderate or severe.

“More research will be conducted together with other independent and EU-funded research to shed light on the causes of narcolepsy, such as how the vaccine might be able to trigger or unmask the condition.”

Vytenis Andriukaitis, EU Commissioner for Health and Food Safety

Following the last outbreak, there were huge delays in delivering the pandemic vaccine, Pandemrix, to certain countries. Communicating the risk versus benefits of the vaccine was considered extremely difficult and some nations reported a loss of public confidence in vaccination, in general, the EU found.

It has promised to increase transparency of the decision-making process, especially in relation to vaccine procurement. Although millions of people received the swine flu vaccine Pandemrix in 2009 without complications, it was subsequently shown to have devastating side effects in a number of people, especially children.

Around 1,700 adults and children across Europe are now registered in the EU database of adverse drug reactions as suffering from the lifelong neurological condition narcolepsy following their vaccination.

Mr Andriukaitis said he was upset about hearing from some of the children and their families at a recent meeting in Brussels where they called on him to launch a pan-EU wide inquiry into the cases that were triggered by use of the Pandemrix vaccine to treat the 2009/10 swine flu outbreak.

Almost 1,700 adults and children in total across Europe are registered in the EU database of adverse drug reactions who now suffer from the lifelong neurological condition as a result.

Earlier this month, the government lost a five-year legal battle at the Court of Appeal over vaccine injury payments.

The judgment was handed down following the battle between the Department for Work and Pensions (DWP) and the family of an anonymous child known as ‘John’, following his diagnosis of the incurable neurological condition and an application in 2012 to the government’s compensation scheme under the Vaccine Damage Payment Act.

The DWP had appealed against an order ordering it to pay John, now 14, £120,000 compensation. Many other families, whose cases had been put on hold pending the outcome, should now receive the same compensation.

“I was very sorry and sad to hear again of the terrifying experience of the children and their families – and I expressed my personal words of sympathy to them [in Brussels],” Mr Andriukaitis told i.

EU funding

“In the Commission, we are funding research into the sleep disorders, including narcolepsy, with nearly EUR 30 million allocated through the Seventh Framework and Horizon 2020 research programmes.”

Mr Andriukaitis said epidemiological studies relating to Pandemrix vaccination in several European countries had indicated an increased risk of narcolepsy in vaccinated – as compared with unvaccinated – individuals.

“Patient safety is paramount to me – I am a medical doctor. It is also the absolute priority of the Commission.”

Vytenis Andriukaitis

The commissioner said the marketing authorisation holder, responsible for reviewing and assessing data to support a medicinal product, has committed to continue to collect and submit any new data related to narcolepsy to the European Medicines Agency (EMA), including after the expiry of Pandemrix authorisation in 2015.

“Patient safety is paramount to me – I am a medical doctor,” Mr Andriukaitis said. “It is also the absolute priority of the Commission. And I would like to reassure you that a medicine, including a vaccine, can only be placed on the EU market after an authorisation has been granted based on a positive assessment of the benefit-risk balance related to its use.

“But this is not enough. This is why, after the initial authorisation, the safety of a product is followed during its whole life-cycle. The Commission and the Member States work together in the Health Security Committee to strengthen pandemic influenza preparedness and crisis management in the EU by updating national pandemic influenza preparedness plans. To this end, work on a guide for influenza pandemic plan will be finalised in the committee soon.”

Further research needed

Mr Andriukaitis said GSK, the makers of Pandemrix, has carried out further research into the link between its drug and narcolepsy.

“More will be conducted together with other independent and EU-funded research to shed light on the causes of narcolepsy, such as how the vaccine might be able to trigger or unmask the condition. All data will be reviewed by EMA’s Committee for Medicinal Products for Human Use as soon as they become available.

“As European decision-makers, our constant objective is to prevent such terrible situations from occurring again.”

Claire Crisp, whose daughter Mathilda needs round the clock care after she developed narcolepsy following her Pandemrix vaccination, said she could only take comfort in another swine flu vaccination program if various measures were guaranteed.

They include “complete transparency” on behalf of the manufacturers GSK and the EU with respect to the content of the vaccine and potential side effects with the information available to every consenting patient.

“I am not anti-vaccine. I am pro-health, pro-science and pro-choice when it comes to vaccinations,” she said.

“Parents should have access to information pertaining to the content of vaccines and whether or not clinical trials were completed. The lack of transparency and honesty on behalf of GSK and the British government harmed hundreds of children who have been devastated by an incurable neurological disorder that requires round the clock treatment. This must never happen again.”

What is swine flu?

Swine flu is an infection caused by any one of several types of swine influenza viruses, the best known arguably the H1N1 virus. It is a respiratory disease caused by influenza viruses that infect the respiratory tract of pigs and result in a barking cough, decreased appetite, nasal secretions, and listless behavior.

The virus can be transmitted to humans.

Swine flu was initially seen in humans in Mexico in 2009. The virus appeared to be a new strain of H1N1 which resulted when a previous triple reassortment of bird, swine and human flu viruses further combined with a Eurasian pig flu virus, leading to the term “swine flu”.

Unlike most strains of influenza, H1N1 does not disproportionately infect adults older than 60. This was an unusual and characteristic feature of the H1N1 pandemic. Even in the case of previously very healthy people, a small percentage will develop pneumonia or acute respiratory distress syndrome (ARDS).

So Much For Ben Goldacre’s AllTrials …




Trials by year

Since Jan 2006, GlaxoSmithKline completed 809 eligible trials and hasn’t published results for 183 trials. That means 22.6% of its trials are missing results. See all its completed trials on ClinicalTrials.gov .

Who’s not sharing their trial results?

Trials registered on ClinicalTrials.gov should share results on the site shortly after completing, or publish in a journal. But many organisations fail to report the results of clinical trials. We think this should change. Explore our data (last updated October 2016) to see the universities, government bodies and pharmaceutical companies that aren’t sharing their clinical trial results.

Trial sponsors

We’ve ranked the major trial sponsors with the most unreported trials registered on ClinicalTrials.gov. Click on a sponsor’s name to find out whether it’s getting better at reporting completed trials – or worse.

Good News For Pandemrix Victims…


A court ruling has paved the way for almost 100 UK victims of a trial vaccine to receive substantial compensation.

The Court of Appeal rejected a government bid to overturn a defeat in a lower court in 2015 that led to £120,000 being awarded to a boy damaged by the Pandemrix vaccine aged seven.

The child, now 14 and known only as John, developed narcolepsy after being given the vaccine during the 2009-10 swine flu pandemic.

The case, brought by London law firm Hodge Jones & Allen, is seen as test case that will trigger payments under the Vaccine Damage Payments Act to all 94 known victims.

It is also likely to lead to civil claims against Pandemrix manufacturer Glaxo-SmithKline.

The Government previously agreed to indemnify the drugs giant against claims at the time the vaccine was released for use on six million  Britons, mainly the young and elderly or patients at risk of swine flu.

The link with narcolepsy was then unknown.

The Department for Work and Pensions had accepted the vaccine caused narcolepsy in John but denied his disabilities were bad enough to pass a 60 per cent threshold to trigger a payout.

Today’s ruling, from three appeal justices headed by Master of the Rolls Sir Terence Etherton, said the lower court was “quite right” to dismiss the Government’s previous attempt to overturn a ruling in favour of John.

Solicitor Peter Todd, who brought the case, told the Standard: “I am pleased the Secretary of State’s appeal has been rejected as his arguments would have made it virtually impossible for genuine cases to obtain any compensation.”

The DWP said: “We are aware of the judgment of the court and are carefully studying the court’s reasons.”

Adam Cartwright, 47, a surveyor and father of two from Horley, Surrey, one of the victims awaiting the outcome of John’s case, told the Standard: “What I want is an admission and an apology, and for them to say, ‘We did do something wrong’.”


How Many Avandia Deaths?…

How many Seroxat/Paxil deaths? and how much harm?

How much Myodil dye caused agonizing disablement to how many people?

How many Pandemrix cases of Narcolepsy in kids?

How much Tafenoquine damage to soldiers?

How many millions will you have when you retire Sir Witty?

What price is human life?



We need transparent trials to keep confidence in medicine

Controversies about the safety of medicines given to millions of people can’t be settled unless data is made more freely available

heart art
Putting your heart into it

Simon Danaher

TENS of millions of people took Vioxx for their arthritis between 1999 and 2004. Tens of thousands probably had a heart attack as a result. It was a similar story with the anti-diabetes drug Avandia. In both cases, the drugs’ makers were accused of withholding trial data that would have revealed the risks to doctors and patients.

Access to data is at the centre of many controversies in modern medicine – not just to do with the usefulness of drugs, but also of treatments (such as exercise for chronic fatigue syndrome) and screening programmes (for breast cancer in younger women, say). Big trials are hard to organise, and so researchers often keep a tight grip on the data they create.

As preventative medicine has become more common, concerns have risen that we may be missing key evidence about the effects of drugs given to huge numbers of people. Recently, statins – given to manage cholesterol levels in those deemed at risk of heart attacks – have come under scrutiny.

The trials run to assess statins’ efficacy didn’t focus on possible adverse effects. Those most worried about these – debilitating muscle pain is often cited – have so far been unable to assess the data for themselves. Other critics say there isn’t strong enough evidence for mass prescription of statins (see “Cholesterol wars: Does a pill a day keep heart attacks away?“).

That has provoked a furious war of words with those who do have access to the data. They say complex ownership and usage conditions mean it can’t be released widely. That’s a familiar problem: similar issues dogged the release of raw data from the 2011 PACE trial of chronic fatigue syndrome treatments, which a tribunal finally ordered to be released last year.

So the controversy over statins, whether well founded or not, rages on with no resolution in sight, damaging confidence in medicine. This simply isn’t good enough. When it comes to treatments for millions, data should be gathered with a view to its eventual release. That won’t be easy. But evidence-based medicine requires no less.

This article appeared in print under the headline “Hearts on our sleeves”

GSK’s Tafenoquine… Another Scandal Emerging?

The Townsville RSL hosted a national health forum to discuss use of controversial use of two anti-malaria drugs. Speaker Stuart McCarthy. Picture: Zak Simmonds
The Townsville RSL hosted a national health forum to discuss use of controversial use of two anti-malaria drugs. Speaker Stuart McCarthy. Picture: Zak Simmonds

Pilot outreach program rejected

A PROPOSAL for a pilot outreach program to help veterans affected by antimalarial drugs has been rejected, with the Department of Veterans’ Affairs saying existing support services are adequate.


The decision has angered veterans who participated in controversial ADF sanctioned mefloquine and tafenoquine trials, and their families, some of whom are caring for those with mental health issues.

They now want to meet with Prime Minister Malcolm Turnbull, who has previously committed to tackling veteran suicides, an issue linked to the use of the drugs.

Lavina Salter, whose husband Chris has suffered adverse mental health after taking mefloquine during a deployment to East Timor, said the proposal rejection had left her feeling defeated.

“By their own admission, DVA has said they don’t know the full extent of the number of veterans affected by these drugs so why don’t they do something?” she said.

“We will keep trying because we can’t give up on these guys.”

The Quinoline Veterans and Families Association submitted a proposal to Veterans’ Affairs Minister Dan Tehan in December for a first-of-its-kind Veterans Outreach Program. The initial budget was $2.25 million per annum for an initial period of five years.

The program would include new research, the identification of all personnel administered mefloquine or tafenoquine during their ADF service and assist affected individuals.

QVFA co-convenor Major Stuart McCarthy, who was prescribed both mefloquine and tafenoquine by the ADF, said rejecting the program was “indefensible” because existing services were clearly not adequate.

“I can accept that Dan Tehan wouldn’t necessarily have signed up to the proposal straight away, but to come back with a blunt no and to not enter into further discussion or dialogue is unacceptable,” he said.

“We have made repeated efforts to engage with DVA and work with them to develop health outreach both for veterans and their families and that’s why we did the proposal because those needs are not being met.

“It’s really time now for the Prime Minister to provide leadership on this, because the departments of Defence and Veterans’ Affairs have completely failed.”

In a short statement, Mr Tehan told the Bulletin yesterday he believed the Federal Government was already responding to concerns about the use of mefloquine by the ADF.

“The existing services and additional support the Government has implemented are meeting the needs of the ex-service community concerned,” he said.

Doctor Calls Out Paxil (Seroxat) And Its Damage To Teens..

Years ago, Big Pharma company SmithKline Beecham (now part of GlaxoSmithKline) published a prominent study in the Journal of the American Academy of Child and Adolescent Psychiatry that concluded the popular antidepressant medication, Paxil, was safe and effective for teenagers.

But in September 2015, the British Medical Journal posted a re-analysis of the original data — and concluded that the opposite is true.

There have been many reports of young people taking or withdrawing from antidepressants, especially Paxil, and committing violent acts, even suicide.

The original study compared the responses of adolescents taking Paxil or a placebo to a group taking an older antidepressant called imipramine. The Paxil group did not perform better than the other groups for depression.

After the study was published, SmithKline Beecham submitted the trial to the FDA for approval in treating adolescents.

Of course, the FDA approved their application and Big Pharma ramped up their marketing of Paxil for teenagers.

Guess what happened next? Prescriptions of antidepressants to our youth increased by 36 percent from 2002 to 2003.

The 2015 article that reanalyzed the data reported that Paxil has no clear effectiveness, and there was mislabeling of serious side effects.

Antidepressant drugs are a disaster. They barely perform better than a placebo. Exercise outperforms antidepressants in nearly every study that compares the two.

I don’t think these drugs need to be pulled from the market completely, but they should not be as widely prescribed.

There are many natural therapies that can combat depression. The best therapy starts with the basics: Drink an adequate amount of water and eat a healthy diet.

In Memory Of Adrian Keegan..




Adrian Keegan’s life was cut short from Seroxat.

Today would have been his 35th birthday.

GSK have never apologized to the families of those killed, or harmed, from Seroxat suicides or side effects. They have never apologized for Study 329, a bogus Seroxat (Paxil) study which was touted to psychiatrists and doctors as a successful study promoting the treatment of Seroxat to adolescents.

Why were Adrian’s parents not warned about the dangers of Seroxat?

I think the parents of Adrian, and the families of all the other Seroxat victims, and the victims themselves- deserve an apology from GSK don’t you?


“..One of the cases that sparked fears was that of Adrian Keegan, 19, who had been taking the drug for 26 days when he committed suicide. In 2001, following the breakdown of his relationship with his girlfriend, he was diagnosed with depression and prescribed Seroxat by his GP. His father Christopher found his body hanging in his flat.

Mr Keegan, from Market Drayton, Shropshire, said: “There needs to be more information and better control as it is given out far too easily, like sweets.””..

This has always been obvious to me…

This perspective has always been obvious to me, and talk to most depressed people and you’ll find it has been obvious to them also… however it’s nice to see the truth about depression being discussed…

so many needless psych-drug prescriptions and so many needless SSRI deaths…


Psychologists Think They Found the Purpose of Depression


Photo: Julia Davila-Lampe/Getty Images

Depression is pervasive: In 2015, about 16 million — or 6.7 percent of — American adults had a major depressive episode in the past year. Major depression takes the most years off of American lives and accounts for the most years lived with disability of any mental or behavioral disorder. It is also expensive: From 1999 to 2012, the percentage of Americans on antidepressants rose from an estimated 6.8 to 12 percent. The global depression drug market is slated to be worth over $16 billion by 2020.

The National Institute of Mental Health defines a major depressive episode as “a period of two weeks or longer during which there is either depressed mood or loss of interest or pleasure, and at least four other symptoms that reflect a change in functioning, such as problems with sleep, eating, energy, concentration, and self-image.” This falls in line with what Matthew Hutson, in a new feature for Nautilus, describes as the disease model of depression: that depression is “a breakdown, a flaw in the system, something to be remedied and moved past.” In his compelling and challenging piece, Hutson profiles several researchers who advance an argument that depression can serve a possibly positive purpose in the lens of evolution. But rather than deifying evolution and trying to scry out what it meant for us, let’s focus on what’s more immediately useful for lived humans lives today: that, in some circumstances, depression may be, in the arc of a life, yielding of insights and personal meaning. All of this is in no way meant to minimize the suffering that depression can cause — but to suggest the uses that it may serve.

At the center of Hutson’s piece is Paul Andrews, an evolutionary psychologist at McMaster University in Canada. Andrews argues that depression may be “an adaptation for analyzing complex problems.” He sees it in the condition’s bouquet of symptoms, which include “anhedonia,” or an inability to feel much pleasure; people who are depressed ruminate frequently, often in spirals; and they get more REM sleep, a phase associated with memory consolidation. This reflects an evolutionary design, the argument goes, one that’s to, as Hutson summarizes, “pull us away from the normal pursuits of life and focus us on understanding or solving the one underlying problem that triggered the depressive episode.” Like, say, a “failed” relationship. The episode, then, is a sort of altered state, one different from the hum of daily life, one that’s supposed to get you to pay attention to whatever wounding led to the upset. For example, 80 percent of subjects in a 61-person study of depression found that they perceived some benefit from rumination, mostly assessing problems and preventing future mistakes.

For now, Andrews’s “analytical rumination hypothesis” is just that, a hypothesis, a term that combines the Greek hypo (under) with –thesis (placing). It’s a concept, an observation, one that acts as a structure for further inquiry. Still, already, there is something very powerful, and even actionable, in reconceptualizing (some) depressive episodes as having a function, as presenting a quest toward understanding for the sufferer to undertake. Other research helps to refract the light being shined here: Laura King, a psychologist at the University of Missouri, has spent a couple decades studying people’s experiences of meaning in life, and she told me in an interview at this year’s Society for Personality and Social Psychology meeting that the meaning people derive from difficult experiences depends not on the amount that they’re suffered, but the extent of reflection — or meaning-making — they’ve done on what prompted a given nadir. Following this logic, if the job of a depressive episode is to figure out what’s gone awry, what emotional knots need to be untangled, what attachment patterns need to be identified and addressed, then antidepressants are an incomplete treatment, just like you wouldn’t prescribe Percocet to a heal a broken ankle without also supplying a cast.

There are even larger, structural issues around the culture and industry of mental health at work here: If the healing of depression requires not just an alleviation of symptoms but a reworking of patterns within a person’s psychology, that’s a deeply subjective rather than objective process, meaning that the scientific method may have difficulty accessing it, and since it’s not objective, it’s perceived as less real or true, since it resides in your interiority, not out there in the readily testable world. Also, therapy — whether cognitive behavioral or psychoanalytic — requires lots of money and lots of time and is not, to say the least, well-supported by insurance companies in the U.S.

Still, this framing of depression as a space for reflection is empowering, and lends a degree of agency to the person being pressed down. Like anxiety, depression might be trying to tell you something. The language of therapeutic traditions is useful: a Jungian analyst would describe depression as katabasis, an Ancient Greek word for descent. Like Orpheus heading to Hades or Luke Skywalker in the swamps of Dagobah, it’s a journey into the underworld, where the adventurer is to “go through the door … immerse himself in the wound, and exit from his old life through it,” like Robert Bly writes in Iron John. Since it is subjective, the problems and solutions will be personal — of the person and their particular psychological history — and thus demand the individualized understanding of the sufferer of depression, perhaps with the assistance of a skilled therapist. That’s another theme: While disengagement from emotionality characterizes depression and other disorders, engagement with one’s inner world looks to to be the way out. Put more poetically: You exit through the wound.

“Most episodes of depression end on their own — something known as spontaneous remission,” Vanderbilt psychologist Steven Hollon tells Nautilus, noting that the depression-as-adaptation narrative may explain why. Indeed, “cognitive behavioral and problem-solving therapies may work precisely because they tap into and accelerate — in a matter of weeks — the very processes that have evolved to occur over the space of months,” he added. Katabasis leads to catharsis; not coincidentally, there’s a shared theme in the personal narratives of people who reach midlife with a sense of well-being and generativity toward others: redemption.

Hello To The World Health Organization (WHO)…

I get views regularly from organizations as diverse as the WHO (World Health Organization) and the MHRA, to the US government and the European Medicines Authority. It’s interesting that the WHO were viewing today, because it was back in 2002, that the WHO reported that Paroxetine (Seroxat/Paxil) topped the list of withdrawal symptoms for SSRI drugs.



“Dr Healy told BBC News Online, of the 100m people world-wide who were on Seroxat, one in 1,000 could have a suicidal reaction.”

Withdrawal problems

A World Health Organization report which ranked antidepressants in order of withdrawal problems found Seroxat was the hardest to come off.



the ecosystem approach to obgyn

My Life in my 60's

Finding joy in my 60's

The Vile Mint

Poetry, Short Stories and Violent Ideas



Rebel City Writers

A radical perspective on local, national and international issues from the pens of a few disgruntled agitators!

Critical Dispatches

Reports from my somewhat unusual life

~ L to the Aura ~

sustainability. compassion. inspiration.

Heroes Not Zombies

becoming not being.......

DES Daughter Network

Because Social Media increases Awareness and brings the DES Community Together

recovery network: Toronto

people can and do recover from what is sometimes called "mental illness"

Deidra Alexander's Blog

I have people to kill, lives to ruin, plagues to bring, and worlds to destroy. I am not the Angel of Death. I'm a fiction writer.

%d bloggers like this: